DocGo (DCGO) Q1 2026 earnings review
Base Revenue Thrives, but the Cost of Growth is Punishing Margins
DocGo has successfully completed its transition away from migrant contracts. Total revenue declined 21% YoY to $75.6M due to this phase-out, but core base revenue grew a robust 19.3%. While top-line volume is recovering—prompting management to raise full-year revenue guidance—profitability remains entirely absent. The Adjusted EBITDA loss widened to $10.2M as the company absorbed heavy hiring costs, incentive pay, and rising fuel expenses to support the volume surge. The runway is getting shorter: cash dropped to $59.9M. DocGo is in a race to hit its targeted H2 2026 profitability inflection point before liquidity concerns overshadow the operational pivot.
🐂 Bull Case
The company generated $0 from migrant-related programs in Q1, meaning all future growth represents sustainable core operations. Core Mobile Health revenue rocketed 131% YoY.
Strong across-the-board volume metrics (home healthcare +46%, virtual care +37%) gave management confidence to raise the 2026 revenue guidance midpoint by $7.5M.
🐻 Bear Case
Despite stripping out lower-margin legacy contracts, Adjusted EBITDA loss expanded to $10.2M (from $3.9M last year). Growth is currently coming at the direct expense of margins.
Total cash dropped again sequentially to $59.9M. With ongoing operating losses, the company has limited breathing room before requiring a strategic transaction or outside capital.
⚖️ Verdict: 🔴
Bearish. The successful pivot to core revenue is a significant milestone, but the business model currently lacks operating leverage. Management is essentially buying revenue growth with aggressive hiring and incentives, burning through a dwindling cash reserve while awaiting an uncertain strategic alternative process.
Key Themes
SteadyMD and Virtual Care Scaling Rapidly
The integration of SteadyMD is Accelerating top-line results. Mobile Health base revenue jumped 131% YoY to $23.6M. SteadyMD secured a new contract with a major online pharmacy for weight loss prescriptions and general clinical services, and management now projects its top-line growth will exceed 50% for the full year.
Medical Transportation Volumes Provide Stability
The foundational Medical Transportation segment is Stable and growing, with revenue reaching $51.9M. U.S. medical transportation volumes grew 17% YoY. As the company continues to backfill staff and capture previously outsourced routes, this segment acts as the primary cash flow stabilizer.
Payer Business Footprint Expanding
The long-term play into population health is Accelerating. DocGo surpassed 1.6 million assigned patients for care gap closure services, up from 1.45 million in 25Q4. Coupled with participation in the CMS ACCESS Model program for chronic disease management, the recurring revenue pipeline is solidifying.
Growth is Destroying Margin Efficiency
A severe contradiction exists between the positive volume narrative and the bottom line. Management admitted that accelerated growth actively hurt immediate margins, widening the Adjusted EBITDA loss to $10.2M. The company is relying on temporary workforce incentives and an increased pace of hiring to fill capacity gaps, proving the model currently lacks true scalability.
Cash Burn Severely Tightening Runway
Total cash and cash equivalents are Decelerating rapidly, falling to $59.9M from $68.3M at the end of 2025 (and down from $103M in 25Q1). While management cited post-quarter collections of lingering migrant receivables, the structural cash burn from operations puts immense pressure on their ability to self-fund until the projected H2 profitability turn.
Macro Pressures Impacting Fleet Economics
CFO Norm Rosenberg explicitly pointed to a meaningful negative impact from rising fuel prices, attributed to the war in the Middle East. For a company heavily reliant on a vast ambulance and mobile health vehicle fleet, this uncontrollable macro headwind directly compresses gross margins in the transportation segment.
Strategic Alternatives Process Looming
The Board's ongoing 'strategic alternatives' process continues. The appointment of Michael Burdiek as incoming Board Chair and the creation of an operational review subcommittee suggests an intensified push to aggressively cut costs to make the company a more attractive acquisition target.
Other KPIs
Decelerating slightly from 32.1% in Q1 2025. Margin deterioration was primarily driven by higher labor and fuel costs, offsetting the positive mix shift away from lower-margin migrant contracts.
Accelerating sequentially by 36% from $12.8 million in 25Q4. This metric bundles care gap closures, remote patient monitoring, and mobile phlebotomy, representing the core growth engine for future higher-margin services.
Guidance
Accelerating compared to prior guidance of $290 - $310M. This implies roughly flat YoY performance relative to FY25's $322M, but adjusting for the loss of $68M+ in migrant revenue from last year, it requires core base business growth approaching 20%.
Stable compared to prior guidance. However, because the company already posted a $10.2M loss in Q1 alone, achieving this full-year target mathematically requires a Reversing trend to significant positive EBITDA generation in the back half of the year. This represents immense execution risk.
Key Questions
EBITDA Math for FY26
With a $10.2M Adjusted EBITDA loss already incurred in Q1, achieving the full-year target of ($5M) to ($10M) implies aggressive profitability in H2. How much of this improvement relies on unproven SG&A cost cuts versus natural margin expansion?
Cash Runway and Liquidity
Cash has depleted to $59.9M. Can you quantify the specific amount of final migrant-related receivables collected subsequent to quarter-end, and what is the projected lowest cash trough before achieving positive operating cash flow?
Hiring Inefficiencies
You cited the use of incentives to bridge staffing gaps as new full-time hires enter the field. What is the expected duration of this 'margin inefficiency' phase, and when will staffing levels normalize to support your double-digit margin targets?